{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:51:31Z","timestamp":1790949091881,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ijrobp.2024.06.030","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T12:27:37Z","timestamp":1720096057000},"page":"1394-1403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study"],"prefix":"10.1016","volume":"120","author":[{"given":"Stefano","family":"Arcangeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Chissotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Purrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo Ray","family":"Colciago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9584-637X","authenticated-orcid":false,"given":"Valeria","family":"Faccenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Panizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2024.06.030_bib0001","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2018.12.045","article-title":"Five-year outcomes of a phase 1 dose-escalation study using stereotactic body radiosurgery for patients with low-risk and intermediate-risk prostate caner","volume":"104","author":"Zelefsky","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0002","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2016.02.014","article-title":"Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial","volume":"59","author":"Hannan","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2020.01.029","article-title":"Target motion mitigation promotes high-precision treatment planning and delivery of extreme hypofractionated prostate cancer radiotherapy: Results from a phase II study","volume":"146","author":"Greco","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0004","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2021.03.025","article-title":"A multi-institutional phase 2 trial of high-dose SAbR for prostate cancer using rectal spacer","volume":"111","author":"Folkert","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.euo.2022.02.005","article-title":"Local failure after prostate SBRT predominantly occurs in the PI-RADS 4 or 5 dominant intraprostatic lesion","volume":"6","author":"Gorovets","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0006","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0007","doi-asserted-by":"crossref","first-page":"S2647","DOI":"10.1016\/S0167-8140(24)03366-8","article-title":"Focal boost RT in men with intermediate and high-risk PCA: 5-year results of the hypo-FLAME trial","volume":"1","author":"Draulans","year":"2024","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0008","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1007\/s00345-023-04579-6","article-title":"State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: A systematic review of literature","volume":"41","author":"Le Guevelou","year":"2023","journal-title":"World J Urol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0009","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1533034616649495","article-title":"Interfraction anatomical variability can lead to significantly increased rectal dose for patients undergoing stereotactic body radiotherapy for prostate cancer","volume":"16","author":"Wahl","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijrobp.2021.06.037","article-title":"Radiation dose to the intraprostatic urethra correlates strongly with urinary toxicity after prostate stereotactic body radiation therapy: A combined analysis of 23 prospective clinical trials","volume":"112","author":"Leeman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0011","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/cancers15041153","article-title":"Dosimetric impact of intrafraction prostate motion and interfraction anatomical changes in dose-escalated Linac-based SBRT","volume":"15","author":"Faccenda","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.883725","article-title":"Intrafraction prostate motion management during dose-escalated Linac-based stereotactic body radiation therapy","volume":"12","author":"Panizza","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.radonc.2017.06.014","article-title":"Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer","volume":"124","author":"Hoskin","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0014","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.radonc.2016.04.006","article-title":"High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results","volume":"119","author":"Prada","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijrobp.2016.08.011","article-title":"Favorable preliminary outcomes for men with low- and intermediate-risk prostate cancer treated with 19-Gy single-fraction high-dose-rate brachytherapy","volume":"97","author":"Krauss","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0016","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.radonc.2020.02.009","article-title":"Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy","volume":"146","author":"Morton","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0017","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","article-title":"Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: Results from the PROSINT phase 2 randomized clinical trial","volume":"7","author":"Greco","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0018","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Prostate cancer. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed April 1, 2023."},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0019","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0020","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA."},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0021","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0022","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1016\/j.ejca.2008.07.030","article-title":"An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer","volume":"44","author":"van Andel","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijrobp.2006.03.055","article-title":"Acute and late gastrointestinal toxicity after radiotherapy in prostate cancer patients: consequential late damage","volume":"66","author":"Heemsbergen","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0024","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): Acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0025","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: Planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0026","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.ijrobp.2019.02.010","article-title":"Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low- and intermediate-risk prostate cancer","volume":"104","author":"Siddiqui","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0027","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ijrobp.2019.02.033","article-title":"Phenotype-oriented ablation of oligometastatic cancer with single dose radiation therapy","volume":"104","author":"Greco","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0028","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ijrobp.2021.01.004","article-title":"Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 Gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer","volume":"110","author":"Zelefsky","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0029","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/s41391-021-00328-1","article-title":"Treating the patient and not just the cancer: therapeutic burden in prostate cancer","volume":"24","author":"Spratt","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12894-024-01421-y","article-title":"Converting between the International Prostate Symptom Score (IPSS) and the Expanded Prostate Cancer Index Composite (EPIC) urinary subscales: Modeling and external validation","volume":"24","author":"Windisch","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0031","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s11136-014-0678-8","article-title":"Assessing quality of life in patients with prostate cancer: a systematic and standardized comparison of available instruments","volume":"23","author":"Schmidt","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0032","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ijrobp.2023.06.250","article-title":"To boost or not to boost: pooled analyses from 2-fraction SABR trials for localized prostate cancer","volume":"117","author":"Ong","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0033","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ijrobp.2023.03.057","article-title":"Every-other-day versus once-a-week urethra-sparing prostate stereotactic body radiation therapy: 5-year results of a randomized phase 2 trial","volume":"117","author":"Zilli","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0034","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1007\/s00261-019-02194-x","article-title":"Apical periurethral transition zone lesions: MRI and histology findings","volume":"45","author":"Tuncer","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13014-015-0426-4","article-title":"Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)","volume":"10","author":"Nicolae","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109503","article-title":"Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trial","volume":"181","author":"Ong","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0037","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijrobp.2021.03.027","article-title":"Toxicity at 1 year after stereotactic body radiation therapy in 3 fractions for localized prostate cancer","volume":"111","author":"Magli","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0038","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bju.15821","article-title":"Comprehensive review of the use of hydrogel spacers prior to radiation therapy for prostate cancer","volume":"131","author":"Harvey","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0039","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ijrobp.2009.03.007","article-title":"Inferences about prostate intrafraction motion from pre- and posttreatment volumetric imaging","volume":"75","author":"Adamson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0040","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.prro.2023.08.011","article-title":"Stereotactic body radiation therapy: A Radiosurgery Society guide to the treatment of localized prostate cancer illustrated by challenging cases","volume":"14","author":"Ma","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0041","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ajic.2020.07.034","article-title":"Antibiotic prophylaxis after extraction of urinary catheter prevents urinary tract infections: A systematic review and meta-analysis","volume":"49","author":"Liu","year":"2021","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0042","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0043","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1470-2045(20)30581-7","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): Patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial","volume":"22","author":"Fransson","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0044","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0045","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2023.09.032","article-title":"Interim toxicity analysis from the randomized HERMES trial of 2- and 5-fraction magnetic resonance imaging-guided adaptive prostate radiation therapy","volume":"118","author":"Westley","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0046","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2019.07.018","article-title":"Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial","volume":"139","author":"Zilli","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110181","article-title":"ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I\/II trial","volume":"194","author":"Zilli","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0048","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: The MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0049","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ijrobp.2014.10.049","article-title":"Continuous monitoring and intrafraction target position correction during treatment improves target coverage for patients undergoing SBRT prostate therapy","volume":"91","author":"Lovelock","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0050","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/cancers16010013","article-title":"Treatment optimization in Linac-based SBRT for localized prostate cancer: A single-arc versus dual-arc plan comparison","volume":"16","author":"Panizza","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0051","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1088\/0031-9155\/58\/14\/4921","article-title":"Reduction of prostate intrafractional motion from shortening the treatment time","volume":"58","author":"Li","year":"2013","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2024.06.030_bib0052","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2018.07.003","article-title":"Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: A systematic review and metanalysis of randomized clinical trials","volume":"70","author":"Arcangeli","year":"2018","journal-title":"Cancer Treat Rev"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624025392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301624025392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T18:27:50Z","timestamp":1731608870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301624025392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0360301624025392"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.06.030","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ablative Radiation Therapy for Unfavorable Prostate Tumors (ABRUPT): Preliminary Analysis of Toxicity and Quality of Life from a Prospective Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2024.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}